Merck and Schering Say Enhance Study Misses Significance
83518
Merck & Co and Schering-Plough Corp said a closely watched study involving its Vytorin cholesterol treatment failed to reach its main goal.
319964
The embattled pharmaceutical industry announced its intention Thursday to publish more data about clinical drug trials, despite skepticism about whether the initiative will really increase transparency and improve drug safety.
114045
The diabetes drugs Actos and Avandia raise the risk of heart failure but do not increase the risk of heart-related death, U.S. researchers said on Thursday, confirming earlier findings.
468679
Fueling the continuing debate over the safety of the popular hepatitis B vaccine, a new study suggests that it contributes to a tiny increase in the number of multiple sclerosis cases.
565830
Early results from an ongoing study of GlaxoSmithKline Plc's Avandia was unable to show any increase in heart attacks among patients, but several experts said the evidence still suggests the popular diabetes drug raises the risk of heart attack.
398157
An experimental cholesterol treatment touted by drugmaker Merck &amp; Co. significantly reduced artery-clogging fats in late-stage testing, but it got a mixed reception from Wall Street analysts Tuesday.
343561
Recent research shows that antioxidant vitamins may not be as powerful as once thought.
465493
Supplements that millions of Americans take to stave off disease and slow the aging process do not boost longevity and appear to actually increase the risk of dying, according to the most comprehensive study of whether popular "antioxidants" help users live longer.
550692
NEW YORK - Today at the UBS Global Life Sciences Conference, AtheroGenics was met with pointed skepticism over trial results for its drug, AGI-1067.
36441
New evidence shows that drug makers Merck and Schering-Plough never published several studies that raised questions about a cholesterol drugâs risks to the liver.
301160
Transplants of insulin-making cells have not lived up to the promise they showed in an initial trial.
667
The Food and Drug Administration insists that until pharmaceutical giant Merck presented new information this week, there was not enough evidence to pull the arthritis drug Vioxx off the market.
115928
Researchers say results aren't necessarily transferable to human beings.
397329
Pharmaceutical company AtheroGenics Inc. said Wednesday that a mid-stage trial to evaluate its AGIX-4207 treatment for rheumatoid arthritis failed to meet the study&#39;s endpoint, showing no significant improvement compared with placebo.
29990
Nutritional supplements are generally not taken into account when health researchers try to get a snapshot of the nationâs nutritional habits, a new study finds.
388679
A long, suspicious delay in the study of Merck and Schering's $5 billion drug was reported by Forbes in November.
741470
Shares of biotech company Biomira Inc. soared as it and a development partner, German drug maker Merck KGaA, reported Friday that the median survival in a study involving a lung cancer vaccine has yet to be reached after 23 months in a subset of patients.